Table 4.
Multivariable-adjusted Cox regression results for risk of time to MACE or ACM
| Variable | Time to MACE |
Time to ACM |
||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Suboptimal statin therapy | 2.10 (1.25–3.53) | .005 | 2.46 (1.38–4.39) | .003 |
| Age ≥ 75 y | 2.05 (1.36–3.09) | .001 | 3.47 (2.12–5.68) | <.001 |
| NYHA | 1.48 (1.12–1.96) | .006 | 1.62 (1.16–2.27) | .005 |
| Treatment with PCI/CABG | 0.56 (0.37–0.86) | .008 | 0.49 (0.28–0.85) | .011 |
| Prior CVD | 2.00 (1.31–3.04) | .001 | 2.43 (1.45–4.08) | .001 |
| Diabetes mellitus | 1.52 (1.002–2.30) | .049 | – | – |
| Chronic kidney disease | – | – | 1.65 (0.93–2.93) | .089 |
ACM, all-cause mortality; CABG, coronary artery bypass graft surgery; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; MACE, major adverse cardiovascular events; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.
Covariates with P < .1 in univariate Cox analysis were entered into multivariable Cox regression modeling using the forward likelihood ratio method to select the covariate model (variables not in bold font). After these times to MACE or ACM covariate models were selected, the suboptimal statin therapy variable was entered into both models to produce the presented results.